PTSD patients get extended relief: methylone study shows promise for Long-Term control

NCT ID NCT06237426

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study followed 44 people with PTSD who had already completed a prior methylone (TSND-201) trial. Over 52 weeks, researchers checked their symptoms and safety each month. If PTSD symptoms returned, participants could receive more methylone treatment. The goal was to see if the drug can safely manage PTSD over the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

44 people

The number who actually took part.

Started

Mar 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 71 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participation in and successful completion of a prior Transcend-sponsored clinical trial with TSND-201. * Agree to not participate in any other interventional clinical trials for the duration of this study. * Willing and able to provide informed consent. Exclusion Criteria: * Had significant deviation(s)/non-compliance in parent study in the opinion of the Investigator which would deem them unsuitable for participation. * Change or development of any physical or psychological finding that would make participant unsuitable for study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-traumatic stress disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cambridgeshire and Peterborough NHS Foundation Trust

    Cambridge, England, United Kingdom

  • Cedar Clinical Research, Inc

    Draper, Utah, 84020, United States

  • Clerkenwell Health

    London, United Kingdom

  • Kings College

    London, United Kingdom

  • La Nua Mental Health Centre

    Galway, Ireland

  • Mirabilis Health

    Belfast, Northern Ireland, United Kingdom

  • Mountain View Clinical Research

    Denver, Colorado, 80209, United States

  • NHS Greater Glasgow and Clyde

    Glasgow, Scotland, United Kingdom

  • Sunstone Medical

    Rockville, Maryland, 20850, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.